His primary areas of study are Cancer, Immunology, Cancer research, Head and neck squamous-cell carcinoma and Internal medicine. His work deals with themes such as Surgery and Pathology, which intersect with Cancer. The Cancer research study combines topics in areas such as Cell culture, Protein kinase B, Epidermal growth factor receptor, Cancer cell and Gene.
His Head and neck squamous-cell carcinoma study incorporates themes from Receptor and Downregulation and upregulation. His research on Internal medicine frequently connects to adjacent areas such as Oncology. He has included themes like Head and neck, Carcinoma, Chemotherapy and Hazard ratio in his Oncology study.
Internal medicine, Oncology, Head and neck cancer, Cancer research and Cancer are his primary areas of study. In the field of Internal medicine, his study on Cetuximab and Nivolumab overlaps with subjects such as In patient. His Oncology study combines topics from a wide range of disciplines, such as Chemotherapy, Cisplatin, Clinical endpoint, Carcinoma and Stage.
His studies deal with areas such as Clinical trial, Disease and Nuclear medicine as well as Head and neck cancer. The concepts of his Cancer research study are interwoven with issues in Head and neck squamous-cell carcinoma, CD8, Immunology and Immunotherapy. His Cancer research is multidisciplinary, incorporating elements of Surgery and Pathology.
Robert L. Ferris mostly deals with Internal medicine, Cancer research, Head and neck squamous-cell carcinoma, Oncology and Head and neck cancer. His Clinical trial, Hazard ratio and Cohort study study, which is part of a larger body of work in Internal medicine, is frequently linked to In patient, bridging the gap between disciplines. The various areas that Robert L. Ferris examines in his Cancer research study include T cell, CD8, Immune system and Immunotherapy.
His Head and neck squamous-cell carcinoma study which covers Cetuximab that intersects with Methotrexate. His Oncology research includes elements of Pembrolizumab, Chemotherapy, Phases of clinical research, Head and neck and Nivolumab. His study focuses on the intersection of Head and neck cancer and fields such as Stereotactic body radiation therapy with connections in the field of Re-Irradiation and Toxicity.
His scientific interests lie mostly in Internal medicine, Oncology, Head and neck cancer, Immunotherapy and Head and neck squamous-cell carcinoma. He studied Internal medicine and Gastroenterology that intersect with Taxane, Cytology, Predictive value of tests and Thyroid nodules. His Oncology research includes themes of Clinical trial, Chemotherapy, Phases of clinical research, Stage and Nivolumab.
His Head and neck cancer research is included under the broader classification of Cancer. His work carried out in the field of Immunotherapy brings together such families of science as Blockade and Cancer research. His Head and neck squamous-cell carcinoma research is multidisciplinary, relying on both Tremelimumab and Durvalumab.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Robert L. Ferris;George Blumenschein;Jerome Fayette;Joel Guigay.
The New England Journal of Medicine (2016)
Integrated Genomic Characterization of Papillary Thyroid Carcinoma
Nishant Agrawal;Rehan Akbani;B. Arman Aksoy;Adrian Ally.
Head and neck cancer
Athanassios Argiris;Michalis V Karamouzis;David Raben;Robert L Ferris.
The Lancet (2008)
Comprehensive genomic characterization of head and neck squamous cell carcinomas
Michael S. Lawrence;Carrie Sougnez;Lee Lichtenstein;Kristian Cibulskis.
Impact of Mutational Testing on the Diagnosis and Management of Patients with Cytologically Indeterminate Thyroid Nodules: A Prospective Analysis of 1056 FNA Samples
Yuri E. Nikiforov;N. Paul Ohori;Steven P. Hodak;Sally E. Carty.
The Journal of Clinical Endocrinology and Metabolism (2011)
Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers
Vivian W.Y. Lui;Matthew L. Hedberg;Hua Li;Bhavana S. Vangara.
Cancer Discovery (2013)
Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay.
Yuri E. Nikiforov;Sally E. Carty;Simon I. Chiosea;Christopher Coyne.
Lipid accumulation and dendritic cell dysfunction in cancer
Donna L. Herber;Wei Cao;Yulia Nefedova;Sergey V. Novitskiy.
Nature Medicine (2010)
Immunology and Immunotherapy of Head and Neck Cancer
Robert L. Ferris.
Journal of Clinical Oncology (2015)
The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction
Nicole E. Scharping;Ashley V. Menk;Rebecca S. Moreci;Ryan D. Whetstone.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: